I have a hunch this drug has been partnered. Hint all presentations that astex was allowed to post are out. At-13387 the only one missing, that they owned. If I'm right, I see a large milestone rolling in. This drug is in Ph2, it's a second generation compound, that will not cause liver damage. Could we be hearing about the next $500M deal. This should also bring north of $50M upfront. I search to see if at-13387 was a oral presentation, which would explain the non posting.
Free, I emailed TIM asking when At13387 AACR information would be posted. He replied, "author Dr. de Bono has not give Astex permission to post. He is looking to publish." I emailed back, Doesn't Astex own the compound, trial and patient data? Unfair to investors who fund development and Dr. de Bono's work and can not attend AACR. Does his reply make sense?
THe key here is that astex has not posted the update info on their webpage. Why? Not only would this lessen burn, it would pass the costs of at-13387 to the partner. The funds spent the past year would now go towards new trials of future drugs.